Apple Wins Invalidation of Blood-Monitoring Patent After Appeal

Apple Inc. won invalidation of an Omni MedSci Inc. patent covering technology for a wearable device that tracks blood-related metrics, including glucose, after the Federal Circuit revived its challenge.

All claims of US Patent No. 10,517,484 are obvious in light of previous inventions, the Patent Trial and Appeal Board ruled Feb. 14, after the tribunal initially canceled 12 of the patent’s 23 claims in 2022. The US Court of Appeals for the Federal Circuit in June ordered the PTAB to review the upheld portions because the tribunal failed to consider Apple’s alternative claim construction argument.

• Apple petitioned the PTAB in ...